Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2749-2756

  Jones, Dylan T ^a   Trowbridge, Ian S ^b   Harris, Adrian L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CELL SURFACE RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A27.15; MONOCLONAL ANTIBODY E2.3; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL GROWTH; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME MECHANISM; FEMALE; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; HYDROXYLATION; IRON TRANSPORT; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

ANTIBODIES, MONOCLONAL; ASCORBIC ACID; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON; RECEPTORS, TRANSFERRIN; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 33645066360     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3857     Document Type: Article

References (52)

1. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
2. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
3. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-54.
4. Elkins JM, Hewitson KS, McNeill LA, et al. Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1α. J Biol Chem 2003;278:1802-6.
5. Maxwell PH. HIF-1's relationship to oxygen: simple yet sophisticated. Cell Cycle 2004;3:156-9.
6. Cooper CE, Lynagh GR, Hoyes KP, et al. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 1996;271:20291-9.
7. Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004;104:2967-75.
8. Casey JL, Koeller DM, Ramin VC, et al. Iron regulation of transferrin receptor mRNA levels requires iron-responsive elements and a rapid turnover determinant in the 3′ untranslated region of the mRNA. EMBO J 1989;8:3693-9.
9. Trowbridge IS, Shackelford DA. Structure and function of transferrin receptors and their relationship to cell growth. Biochem Soc Symp 1986;51:117-29.
10. Gatter KC, Brown G, Trowbridge IS, et al. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983;36:539-45.
11. Shindelman JE, Ortmeyer AE, Sussman HH. Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 1981;27:329-34.
12. Keer HN, Kozlowski JM, Tsai YC, et al. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol 1990;143:381-5.
13. Ng PP, Dela Cruz JS, Sorour DN, et al. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A 2002;99:10706-11.
14. Trowbridge IS, Domingo DL. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 1981;294:171-3.
15. Domingo DL, Trowbridge IS. Transferrin receptor as a target for antibody-drug conjugates. Methods Enzymol 1985;112:238-47.
16. Sauvage CA, Mendelsohn JC, Lesley JF, et al. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic marine leukemia. Cancer Res 1987;47:747-53.
17. White S, Taetle R, Seligman PA, et al. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res 1990;50:6295-301.
18. Domingo DL, Trowbridge IS. Characterization of the human transferrin receptor produced in a baculovirus expression system. J Biol Chem 1988;263:13386-92.
19. Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994;9:2877-8.
20. Darbari D, Loyevsky M, Gordeuk V, et al. Fluorescence measurements of the labile iron pool of sickle erythrocytes. Blood 2003;102:357-64.
21. Epsztejn S, Kakhlon O, Glickstein H, et al. Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem 1997;248:31-40.
22. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993;82:3610-5.
23. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 1999;274:24147-52.
24. Knowles HJ, Raval RR, Harris AL, et al. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 2003;63:1764-8.
25. Donfrancesco A, Deb G, Dominici C, et al. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990;50:4929-30.
26. Seidman AD, Scher HI, Heinemann MH, et al. Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 1991;68:2561-5.
27. Buss JL, Greene BT, Turner J, et al. Iron chelators in cancer chemotherapy. Curr Top Med Chem 2004;4:1623-35.
28. Dayani PN, Bishop MC, Black K, et al. Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol 2004;67:367-77.
29. Kemp JD. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Histol Histopathol 1997;12:291-6.
30. Trowbridge IS. Transferrin receptor as a potential therapeutic target. Prog Allergy 1988;45:121-46.
31. Moura IC, Lepelletier Y, Arnulf B, et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 2004;103:1838-45.
32. Brown JX, Buckett PD, Wessling-Resnick M. Identification of small molecule inhibitors that distinguish between non-transferrin bound iron uptake and transferrin-mediated iron transport. Chem Biol 2004;11:407-16.
33. Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 2002;22:225-50.
34. Kovar J, Naumann PW, Stewart BC, et al. Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. Pathobiology 1995;63:65-70.
35. Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet 1980;2:390-2.
36. Pahl PM, Horwitz MA, Horwitz KB, et al. Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat 2001;69:69-79.
37. Yang DC, Jiang XP, Elliott RL, et al. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. Anticancer Res 2001;21:1777-87.
38. Trowbridge IS, Collawn J, Jing S, et al. Structure-function analysis of the human transferrin receptor: effects of anti-receptor monoclonal antibodies on tumor growth. Curr Stud Hematol Blood Transfus 1991;58:139-47.
39. Beerepoot LV, Shima DT, Kuroki M, et al. Upregulation of vascular endothelial growth factor production by iron chelators. Cancer Res 1996;56:3747-51.
40. Simonart T, Boelaert JR, Andrei G, et al. Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor development in a xenograft model. Int J Cancer 2002;100:140-3.
41. Lovejoy DB, Richardson DR. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 2003;10:1035-49.
42. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995;86:4295-43065.
43. Richardson DR, Hefter GT, May PM, et al. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol Methods 1989;2:161-7.
44. Giles FJ, Fracasso PM, Kantarjian HM, et al. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 2003;27:1077-83.
45. Le NT, Richardson DR. Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects. Int J Cancer 2004;110:468-9.
46. Ray R, Chen G, Vande Velde C, et al. BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem 2000;275:1439-48.
47. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004;64:6160-5.
48. de Jong L, Albracht SP, Kemp A. Prolyl 4-hydroxylase activity in relation to the oxidation state of enzyme-bound iron. The role of ascorbate in peptidyl proline hydroxylation. Biochim Biophys Acta 1982;704:326-32.
49. Myllyla R, Majamaa K, Gunzler V, et al. Ascorbate is consumed stoichiometrically in the uncoupled reactions catalyzed by prolyl 4-hydroxylase and lysyl hydroxylase. J Biol Chem 1984;259:5403-5.
50. Wilmouth RC, Turnbull JJ, Welford RW, et al. Structure and mechanism of anthocyanidin synthase from Arabidopsis thaliana. Structure (Camb) 2002;10:93-103.
51. Kang JS, Cho D, Kim YI, et al. Sodium ascorbate (vitamin C) induces apoptosis in melanoma cells via the down-regulation of transferrin receptor dependent iron uptake. J Cell Physiol 2005;204:192-7.
52. Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med 2005;19:17-20.